News
BLCM
--
0.00%
--
Talaris Therapeutics Appoints Four Vice Presidents in Areas of Strategic Importance
Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe...
BusinessWire · 1d ago
3 Biotech Penny Stocks to Watch as February Approaches
Feb 24, 2021 (Penny Stocks via COMTEX) -- Will These Biotech Penny Stocks Continue to Make Moves Next Month? With February right around the corner, we see...
Penny Stocks · 2d ago
At 34.5% CAGR, CAR-T Cell Therapy Market Size, Share and Analysis to reach $ 8.92 billion by 2026
Feb 23, 2021 (Market Insight Reports) -- Selbyville, Delaware. The report CAR-T Cell Therapy Market Size and Analysis maintains enhanced dynamics and is...
Market Insight Reports · 3d ago
Regenerative Medicine Market Size Report 2021 by Manufacturer Share, Price, Revenue, Gross Profit and Forecast to 2025
Feb 23, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Regenerative Medicine Market” report...
The Express Wire · 3d ago
Bone Marrow Transplant Rejection Treatment Market Global Growth, Share, Trends, Demand and Analysis Report Forecast 2020 to 2027 By Ameco Research
pune, India, Tue, 23 Feb 2021 01:37:48 / Comserve Inc. / -- Bone Marrow Transplant Rejection Treatment market is segmented by Type, and by Application....
Comserve · 3d ago
Myelodysplastic Syndrome Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 22, 2021 (Market Insight Reports) -- The Global Myelodysplastic Syndrome Market is estimated to register a CAGR of over 9.5% during the forecast period...
Market Insight Reports · 4d ago
Bellicum Pharmac Up 52.8% Since SmarTrend Uptrend Call (BLCM)
SmarTrend identified an Uptrend for Bellicum Pharmac (NASDAQ:BLCM) on December 1st, 2020 at $3.71. In approximately 3 months, Bellicum Pharmac has returned 52.83% as of today's recent price of $5.67.
Comtex SmarTrend(R) · 6d ago
Personalized Cell Therapy Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 17, 2021 (Market Insight Reports) -- The report for Personalized Cell Therapy offers an assiduous analysis of contemporary market trends, driving...
Market Insight Reports · 02/17 14:12
Bone Marrow Transplant Rejection Treatment Market 2021 Top Manufacturers Strategy, Industry Share, Growth Factors, Development Trends and 2027 Forecast| Industry Research Biz
Feb 17, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Bone Marrow Transplant...
The Express Wire · 02/17 05:24
Caspase 9 Market 2021 Industry Supply, Growth, Demand, Size, Applications and Manufacturers Analysis Research Report 2027, Says Industry Research Biz
The Express Wire · 02/17 05:03
Engineered T-Cells Market Expected to Reach $2,124 Million, by 2023
Feb 16, 2021 (Market Insight Reports) -- According to a new report published by Allied Market Research, titled, “Engineered T-Cells Market by Type,...
Market Insight Reports · 02/16 18:30
Amniotic Membrane Market Expected to reach $1,563 Million by 2023
Feb 16, 2021 (Market Insight Reports) -- According to a new report published by Allied Market Research, titled, Amniotic Membrane Market by Product,...
Market Insight Reports · 02/16 18:26
Global Regenerative Medicine Market 2020 Consumption Volume, Competitive Dynamics, Industry Outlook and Forecast 2025
Feb 16, 2021 (CDN Newswire via Comtex) -- Global Regenerative Medicine Market 2020 by Company, Regions, Type and Application, Forecast to 2025 is extremely...
CDN Newswire · 02/16 18:23
Rhabdomyosarcoma Drug Market Size 2021 with Top Countries Data, Trends, Share, Industry Growth, Supply and Manufacturers Analysis Research Report till 2027
Feb 15, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Rhabdomyosarcoma Drug Market”...
The Express Wire · 02/15 05:14
Uptrend Call Working As Bellicum Pharmac Stock Rises 58.5% (BLCM)
Feb 12, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Bellicum Pharmac (NASDAQ:BLCM) on December 1st, 2020 at $3.71. In...
marketwatch.com · 02/12 17:53
$4.17 Billion Engineered T Cells Markets - Global Market Forecast Report 2021-2025
Dublin, Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The "Engineered T Cells Market Research Report by Type, by End...
GlobeNewswire · 02/11 12:03
Bone Marrow Transplant Rejection Treatment Market Size 2021 Analysis by Industry Statistics, Progression Status, Emerging Demands, Recent Trends, Business Opportunity, Share and Forecast to 2025 Says Industry Research Biz
Feb 09, 2021 (The Expresswire) -- Global “Bone Marrow Transplant Rejection Treatment Market” 2021 research report represents a detailed overview of the...
The Express Wire · 02/10 04:50
8-K: BELLICUM PHARMACEUTICALS, INC
(EDGAR Online via COMTEX) -- BELLICUM PHARMACEUTICALS, INC NASDAQ false 0001358403 0001358403 2021-02-09 2021-02-09 UNITED STATES SECURITIES AND EXCHANGE...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/10 00:20
Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin
, /PRNewswire/ -- Ponce Therapeutics, Inc. ("Ponce"), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, has now become operational with the launching of its first R & D program, targeti...
PR Newswire - PRF · 02/08 13:30
Dendritic Cell Cancer Vaccine Market Trends, Drivers, Strategies, Applications and Competitive Landscape 2020-2027
pune, India, Mon, 08 Feb 2021 06:53:28 / Comserve Inc. / -- The Global Dendritic Cell Cancer Vaccine market is segmented by company, region (country), by...
Comserve · 02/08 11:57
Webull provides a variety of real-time BLCM stock news. You can receive the latest news about Bellicum Pharms through multiple platforms. This information may help you make smarter investment decisions.
About BLCM
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.